{"id":458370,"date":"2021-03-16T07:03:13","date_gmt":"2021-03-16T11:03:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458370"},"modified":"2021-03-16T07:03:13","modified_gmt":"2021-03-16T11:03:13","slug":"applied-therapeutics-to-host-virtual-rare-disease-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/","title":{"rendered":"Applied Therapeutics to Host Virtual Rare Disease Forum"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, March  16, 2021  (GLOBE NEWSWIRE) &#8212; Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Virtual Rare Disease Forum on Tuesday, March 23<sup>rd<\/sup>, 2021 from 1:00pm to 3:00pm ET. The event will highlight Applied Therapeutics\u2019 development programs in Galactosemia, SORD Deficiency, and PMM2-CDG. The agenda for the event will include:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Update on ACTION-Galactosemia Clinical Development Program<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Overview of SORD Deficiency, presented by Stephan L. Z\u00fcchner, MD, PhD, Professor and Department Chair of Human Genetics at the University of Miami Miller School of Medicine<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Update on SORD Deficiency Clinical Development Plans<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Overview of PMM2-CDG, presented by Joseph Muenzer, MD, PhD, Professor of Pediatric Genetics and Metabolism at University of North Carolina Children\u2019s Research Institute<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt;text-align:justify\">Update on PMM2-CDG Clinical Development Program Plans<\/li>\n<\/ul>\n<p align=\"justify\">\u201cWe\u2019re excited to host this event to spotlight our clinical development programs in Galactosemia, SORD and PMM2-CDG,\u201d said\u00a0Shoshana Shendelman, PhD, Founder, CEO and Chair of the Board of Applied Therapeutics. \u201cWe believe that AT-007 represents an important advancement for patients with these rare diseases, and our clinical development programs offer a unique opportunity to meaningfully impact patients\u2019 lives.\u201d<\/p>\n<p align=\"justify\">An audio webcast of the presentation will be available live. More details will be available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J-M3zmvIJDVVdX6FC9S8KTIRJS7eXqDjnodrtYovPaGolR1UVK9c9Jvkwwv_4fgIhlAQWckXDnA7kmIX6rV1NBVEUtp_ZLEchfzuUenUNKJmZCI3rpsgeDsdrc0Btinp\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>http:\/\/ir.appliedtherapeutics.com<\/u><\/strong><\/a> leading up to the event. An archived version of the presentation will be available following the event.<\/p>\n<p>\n        <strong>About\u00a0Applied Therapeutics<br \/><\/strong>Applied Therapeutics\u00a0is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company\u2019s lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a pivotal Phase 1\/2 clinical trial in\u00a0June 2019, read out positive top-line biomarker data in adult Galactosemia patients in\u00a0January 2020\u00a0and announced full data from the trial in\u00a0April 2020. A pediatric Galactosemia study commenced in\u00a0June 2020. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in\u00a0September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.<\/p>\n<p>To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WkvfxuzRtWiN5fCK01pXRx9oxgfUlCBrCc6CTYTF50AoE4qQeePT11jezhp6Dt0mlQoajWeJdYCCZvWhJXFJQjD2kAVToPTYBzqj5C8CgcZNznAs8NkzwD5eCQaq7E5s\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>www.appliedtherapeutics.com<\/strong><\/a> and follow the company on Twitter <strong><u>@Applied_Tx<\/u><\/strong>.<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Maeve Conneighton<br \/>(212) 600-1902 or<br \/>appliedtherapeutics@argotpartners.com<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>media@appliedtherapeutics.com<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9cb66836-3565-4690-a706-76bd9f042b04\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) &#8212; Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Virtual Rare Disease Forum on Tuesday, March 23rd, 2021 from 1:00pm to 3:00pm ET. The event will highlight Applied Therapeutics\u2019 development programs in Galactosemia, SORD Deficiency, and PMM2-CDG. The agenda for the event will include: Update on ACTION-Galactosemia Clinical Development Program Overview of SORD Deficiency, presented by Stephan L. Z\u00fcchner, MD, PhD, Professor and Department Chair of Human Genetics at the University of Miami Miller School of Medicine Update on SORD Deficiency Clinical Development Plans Overview of PMM2-CDG, presented &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Applied Therapeutics to Host Virtual Rare Disease Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458370","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Applied Therapeutics to Host Virtual Rare Disease Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Applied Therapeutics to Host Virtual Rare Disease Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) &#8212; Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Virtual Rare Disease Forum on Tuesday, March 23rd, 2021 from 1:00pm to 3:00pm ET. The event will highlight Applied Therapeutics\u2019 development programs in Galactosemia, SORD Deficiency, and PMM2-CDG. The agenda for the event will include: Update on ACTION-Galactosemia Clinical Development Program Overview of SORD Deficiency, presented by Stephan L. Z\u00fcchner, MD, PhD, Professor and Department Chair of Human Genetics at the University of Miami Miller School of Medicine Update on SORD Deficiency Clinical Development Plans Overview of PMM2-CDG, presented &hellip; Continue reading &quot;Applied Therapeutics to Host Virtual Rare Disease Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T11:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Applied Therapeutics to Host Virtual Rare Disease Forum\",\"datePublished\":\"2021-03-16T11:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/\"},\"wordCount\":455,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/\",\"name\":\"Applied Therapeutics to Host Virtual Rare Disease Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=\",\"datePublished\":\"2021-03-16T11:03:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-host-virtual-rare-disease-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Applied Therapeutics to Host Virtual Rare Disease Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Applied Therapeutics to Host Virtual Rare Disease Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/","og_locale":"en_US","og_type":"article","og_title":"Applied Therapeutics to Host Virtual Rare Disease Forum - Market Newsdesk","og_description":"NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) &#8212; Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Virtual Rare Disease Forum on Tuesday, March 23rd, 2021 from 1:00pm to 3:00pm ET. The event will highlight Applied Therapeutics\u2019 development programs in Galactosemia, SORD Deficiency, and PMM2-CDG. The agenda for the event will include: Update on ACTION-Galactosemia Clinical Development Program Overview of SORD Deficiency, presented by Stephan L. Z\u00fcchner, MD, PhD, Professor and Department Chair of Human Genetics at the University of Miami Miller School of Medicine Update on SORD Deficiency Clinical Development Plans Overview of PMM2-CDG, presented &hellip; Continue reading \"Applied Therapeutics to Host Virtual Rare Disease Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T11:03:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Applied Therapeutics to Host Virtual Rare Disease Forum","datePublished":"2021-03-16T11:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/"},"wordCount":455,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/","name":"Applied Therapeutics to Host Virtual Rare Disease Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=","datePublished":"2021-03-16T11:03:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDY3NiM0MDY1OTA1IzIxNTY5MDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-host-virtual-rare-disease-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Applied Therapeutics to Host Virtual Rare Disease Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458370"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458370\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}